A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of a Single Dose of ASN100 for the Prevention of Staphylococcus Aureus Pneumonia in Heavily Colonized, Mechanically Ventilated Subjects

Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of a Single Dose of ASN100 for the Prevention of Staphylococcus Aureus Pneumonia in Heavily Colonized, Mechanically Ventilated Subjects

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs ASN 100 (Primary)
  • Indications Staphylococcal infections
  • Focus Therapeutic Use
  • Sponsors Arsanis Biosciences
  • Most Recent Events

    • 26 Apr 2017 According to an Arsanis Biosciences media release, data from this study is anticipated in 2018.
    • 25 Nov 2016 Planned End Date changed from 1 Apr 2018 to 1 Jun 2018.
    • 21 Nov 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top